These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25890786)

  • 21. A newly proposed semi-automated method of grading invasive lobular carcinoma: a unifying concept and correlation with prognostic markers and patient survival.
    Stevens E; Kimler BF; Davis MK; Fan F; Thomas P; Wang XY; Damjanov I; Tawfik OW
    Ann Clin Lab Sci; 2009; 39(1):25-31. PubMed ID: 19201737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy.
    Tamura N; Hasebe T; Okada N; Houjoh T; Akashi-Tanaka S; Shimizu C; Shibata T; Sasajima Y; Iwasaki M; Kinoshita T
    Cancer Sci; 2009 Oct; 100(10):1823-33. PubMed ID: 19604245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study.
    Hasebe T; Imoto S; Yokose T; Ishii G; Iwasaki M; Wada N
    Hum Pathol; 2008 May; 39(5):681-93. PubMed ID: 18329692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas.
    Lehr HA; Rochat C; Schaper C; Nobile A; Shanouda S; Vijgen S; Gauthier A; Obermann E; Leuba S; Schmidt M; C CR; Delaloye JF; Simiantonaki N; Schaefer SC
    Mod Pathol; 2013 Mar; 26(3):336-42. PubMed ID: 23041831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of disease progression in ductal carcinoma in situ of the breast and vascular patterns.
    Adler EH; Sunkara JL; Patchefsky AS; Koss LG; Oktay MH
    Hum Pathol; 2012 Apr; 43(4):550-6. PubMed ID: 21925705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical tumor-stromal fibroblasts in invasive ductal carcinomas of the breast treated with neoadjuvant therapy.
    Hasebe T; Iwasaki M; Akashi-Tanaka S; Hojo T; Shimizu C; Andoh M; Fujiwara Y; Shibata T; Sasajima Y; Kinoshita T; Tsuda H
    Hum Pathol; 2011 Jul; 42(7):998-1006. PubMed ID: 21315415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics.
    Shatat L; Gloyeske N; Madan R; O'Neil M; Tawfik O; Fan F
    Hum Pathol; 2013 Dec; 44(12):2684-9. PubMed ID: 24071019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
    Boyages J; Delaney G; Taylor R
    Cancer; 1999 Feb; 85(3):616-28. PubMed ID: 10091735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors.
    Razek AA; Gaballa G; Denewer A; Nada N
    NMR Biomed; 2010 Jul; 23(6):619-23. PubMed ID: 20232453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast.
    Shimada H; Hasebe T; Sugiyama M; Shibasaki S; Sugitani I; Ueda S; Gotoh Y; Yasuda M; Arai E; Osaki A; Saeki T
    Pathol Int; 2017 Jul; 67(7):331-341. PubMed ID: 28590017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program.
    Schwartz AM; Henson DE; Chen D; Rajamarthandan S
    Arch Pathol Lab Med; 2014 Aug; 138(8):1048-52. PubMed ID: 25076293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
    Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
    Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy.
    Hasebe T; Tamura N; Okada N; Hojo T; Akashi-Tanaka S; Shimizu C; Tsuda H; Shibata T; Sasajima Y; Iwasaki M; Kinoshita T
    Hum Pathol; 2010 Feb; 41(2):262-70. PubMed ID: 19836055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
    Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
    J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
    Falco M
    Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast.
    Yamaguchi J; Ohtani H; Nakamura K; Shimokawa I; Kanematsu T
    Am J Clin Pathol; 2008 Sep; 130(3):382-8. PubMed ID: 18701411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.
    Tawfik O; Kimler BF; Davis M; Stasik C; Lai SM; Mayo MS; Fan F; Donahue JK; Damjanov I; Thomas P; Connor C; Jewell WR; Smith H; Fabian CJ
    Virchows Arch; 2007 Jun; 450(6):627-36. PubMed ID: 17458558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear grade plus proliferation grading system for invasive ductal carcinoma of the breast: validation in a tertiary referral hospital cohort.
    Papadimitriou M; Kaptanis S; Polymeropoulos E; Mitsopoulos G; Stogiannis D; Caroni C; Vaiopoulos G; Panayiotides JG; Karakitsos P
    Am J Clin Pathol; 2015 Dec; 144(6):837-43. PubMed ID: 26572989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers?
    Jiang L; Zhou Y; Wang Z; Lu X; Chen M; Zhou C
    Eur J Radiol; 2013 Sep; 82(9):1404-9. PubMed ID: 23540946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.